Agents Used in Antiretroviral Therapy

  • Authors: Philip Grant, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/1/18 (What's New)

Summary

  • Entry inhibitors block binding of gp120 to CD4 receptors
  • Currently only 1 FDA-approved CCR5 antagonist is available: maraviroc (Table 11)
  • Ibalizumab-uiyk prevents the interaction of gp 120 with CCR5 and CXCR4 and is approved for use in heavily treatment–experienced patients with multidrug-resistant HIV
    • Ibalizumab

    Action required

    Keywords: Initial Antiretroviral Therapy, Special Populations, Treatment Complications, Tropism

    ©2018 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.